NEJM Interview: Peter Ubel on strategies for protecting patients from high out-of-pocket costs for drugs with questionable benefits.
NEJM Interviews
00:00
Intro
This chapter explores the FDA's drug approval process, emphasizing the balance between safety and efficacy while overlooking cost implications. It also contrasts standard and accelerated approval pathways, discussing the potential financial burden on patients from rapidly approved drugs with uncertain benefits.
Transcript
Play full episode
